
ELAN Stock Forecast & Price Target
ELAN Analyst Ratings
Bulls say
Elanco Animal Health is poised for positive growth as its flagship product, Simparica Trio, maintains a dominant market share of over 50%, while the anticipated market share for Credelio Quattro is projected to rise to 16.8% by 2026, demonstrating robust market positioning. Furthermore, the company's Advantage Family and Seresto products have exhibited impressive year-over-year growth rates of 33% and 28%, respectively, in the third quarter of 2025, reflecting ongoing strong demand trends. These factors contribute to a favorable outlook on Elanco's financial prospects, underscoring its competitive advantage in the growing animal health sector.
Bears say
Elanco Animal Health's financial outlook is negatively impacted by potential refinancing risks, as indicated by concerns stemming from Dentsply Sirona's recent bond offering priced at 8.375%, which may affect Elanco’s earnings growth in 2026. Despite a revenue increase of approximately 50%, the company's EBITDA margin has declined by a couple of hundred basis points, reflecting challenges in maintaining profitability. Additionally, while the 2Q EBITDA performance showed an outperformance of $28 million, the overall trend points to pressures on margins that could hinder future earnings stability.
This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELAN Analyst Forecast & Price Prediction
Start investing in ELAN
Order type
Buy in
Order amount
Est. shares
0 shares